Results 151 to 160 of about 1,250,392 (346)
Clobazam versus diazepam: a double‐blind study in anxiety neurosis [proceedings] [PDF]
DR Doongaji+5 more
openalex +1 more source
Gut microbiota and biomarkers are linked to diseases like neurological disorders and metabolic syndromes. Ingestible capsule robots enable minimally invasive gut health assessment. This article proposes a promising direction for the advancement of capsule robots, integrating in situ sampling, real‐time diagnostics, and personalized therapy.
Xizong Chen+3 more
wiley +1 more source
Double Blind Trial of Dextromoramide, Methadone and Pethidine in the Treatment of Severe Pain
S. G. Flavell Matts+2 more
openalex +1 more source
Double-blind evaluation of mazindol in refractory obesity. [PDF]
R. G. Smith+2 more
openalex +1 more source
From Lab to Market: Paper‐Based CRISPR Diagnostics and Commercialization Pathways
Paper‐based CRISPR diagnostics represents one of the most widely commercialized CRISPR assay technologies, yet challenges remain for broader point‐of‐care use. Abstract The global health landscape is continually challenged by infectious diseases that can swiftly escalate into pandemics, underscoring the need for rapid, accurate, and cost‐effective ...
Selen Dalgan, Qingshan Wei
wiley +1 more source
Prophylactic Treatment of Angina Pectoris. A Double-Blind Cross-Over Comparison of Alprenolol and Pentanitrol [PDF]
Axel Aubert+3 more
openalex +1 more source
Evolution of Ocular Organ‐On‐Chip Systems for Disease Modelling and Drug Testing: Where are We Now?
The rise in ophthalmic diseases due to aging, screen use, and environmental factors has driven demand for better ocular models. Traditional systems fall short, encouraging the development of organ‐on‐chip devices. These microfluidic platforms replicate eye tissue architecture, enable drug screening, and simulate ocular diseases.
Sara Trujillo
wiley +1 more source
Comment on "Promises and Partnership" [PDF]
Charness and Dufwenberg (2006) find that promises increase cooperation and suggest that the behavior of subjects in their experiment is driven by guilt aversion.
Cary Deck+2 more
core